Oxigene to begin CA4P lung cancer trial
Massachusetts, USA-headquartered Oxigene says it will conduct a domestic Phase II clinical study of its lead product candidate, Combretastatin (CA4P) as a treatment for stage IIIa/IIIb non-small cell lung cancer.
Initially, the trial will enroll 12 patients who will receive the drug intravenously, in order to establish its tolerability and to determine the most effective dose. The second stage of the study, which will enroll a further 66 patients, will be randomized, open-label and designed to evaluate the compound when given in combination with chemoradiotherapy. The overall aim of the study will be to determine the survival benefit after one year of treatment.
The upcoming trial follows clearance from the UK's Medicines and Healthcare Regulatory Agency to begin Phase III clinical trials of the drug in patients with inoperable stage IIIb/IV NSCLC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze